Idioma:

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis

Alkhazraji, Sondus ; Gebremariam, Teclegiorgis ; Alqarihi, Abdullah ; Gu, Yiyou ; Mamouei, Zeinab ; Singh, Shakti ; Wiederhold, Nathan P ; Shaw, Karen J ; Ibrahim, Ashraf S

Antimicrobial agents and chemotherapy, 2020-02, Vol.64 (3) [Periódico revisado por pares]

United States: American Society for Microbiology

Texto completo disponível

Citações Citado por

Enviar para

Título:
Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
Autor: Alkhazraji, Sondus ; Gebremariam, Teclegiorgis ; Alqarihi, Abdullah ; Gu, Yiyou ; Mamouei, Zeinab ; Singh, Shakti ; Wiederhold, Nathan P ; Shaw, Karen J ; Ibrahim, Ashraf S
Assuntos: Aminopyridines - blood ; Aminopyridines - pharmacokinetics ; Aminopyridines - pharmacology ; Animals ; Antifungal Agents - blood ; Antifungal Agents - pharmacokinetics ; Antifungal Agents - pharmacology ; Biological Availability ; Brain - drug effects ; Brain - immunology ; Brain - microbiology ; Drug Administration Schedule ; Drug Combinations ; Editor's Pick ; Experimental Therapeutics ; Fusariosis - drug therapy ; Fusariosis - immunology ; Fusariosis - microbiology ; Fusariosis - mortality ; Fusarium - drug effects ; Fusarium - growth & development ; Fusarium - immunology ; Half-Life ; Humans ; Immunocompromised Host ; Invasive Fungal Infections - drug therapy ; Invasive Fungal Infections - immunology ; Invasive Fungal Infections - microbiology ; Invasive Fungal Infections - mortality ; Isoxazoles - blood ; Isoxazoles - pharmacokinetics ; Isoxazoles - pharmacology ; Kidney - drug effects ; Kidney - immunology ; Kidney - microbiology ; Lung - drug effects ; Lung - immunology ; Lung - microbiology ; Male ; Mice ; Mice, Inbred ICR ; Microbial Sensitivity Tests ; Prodrugs ; Scedosporium - drug effects ; Scedosporium - growth & development ; Scedosporium - immunology ; Survival Analysis ; Triazoles - pharmacology
É parte de: Antimicrobial agents and chemotherapy, 2020-02, Vol.64 (3)
Notas: Citation Alkhazraji S, Gebremariam T, Alqarihi A, Gu Y, Mamouei Z, Singh S, Wiederhold NP, Shaw KJ, Ibrahim AS. 2020. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother 64:e01735-19. https://doi.org/10.1128/AAC.01735-19.
Sondus Alkhazraji and Teclegiorgis Gebremariam contributed equally. Author order was determined alphabetically.
Descrição: There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to and Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. We evaluated the activity of MGX and the efficacy of the prodrug fosmanogepix (APX001) in immunosuppressed murine models of hematogenously disseminated fusariosis and pulmonary scedosporiosis. The MGX minimum effective concentration (MEC) for isolates was 0.03 μg/ml and ranged from 0.015 to 0.03 μg/ml for isolates. In the scedosporiosis model, treatment of mice with 78 mg/kg and 104 mg/kg of body weight fosmanogepix, along with 1-aminobenzotriazole (ABT) to enhance the serum half-life of MGX, significantly increased median survival time versus placebo from 7 days to 13 and 11 days, respectively. Furthermore, administration of 104 mg/kg fosmanogepix resulted in an ∼2-log reduction in lung, kidney, or brain conidial equivalents/gram tissue (CE). Similarly, in the fusariosis model, 78 mg/kg and 104 mg/kg fosmanogepix plus ABT enhanced median survival time from 7 days to 12 and 10 days, respectively. A 2- to 3-log reduction in kidney and brain CE was observed. In both models, reduction in tissue fungal burden was corroborated with histopathological data, with target organs showing reduced or no abscesses in fosmanogepix-treated mice. Survival and tissue clearance were comparable to a clinically relevant high dose of liposomal amphotericin B (10 to 15 mg/kg). Our data support the continued development of fosmanogepix as a first-in-class treatment for infections caused by these rare molds.
Editor: United States: American Society for Microbiology
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis

Alkhazraji, Sondus ; Gebremariam, Teclegiorgis ; Alqarihi, Abdullah ; Gu, Yiyou ; Mamouei, Zeinab ; Singh, Shakti ; Wiederhold, Nathan P ; Shaw, Karen J ; Ibrahim, Ashraf S

United States: American Society for Microbiology

Buscando em bases de dados remotas. Favor aguardar.